BR112013006936A2 - composto de amida substituída - Google Patents
composto de amida substituídaInfo
- Publication number
- BR112013006936A2 BR112013006936A2 BR112013006936A BR112013006936A BR112013006936A2 BR 112013006936 A2 BR112013006936 A2 BR 112013006936A2 BR 112013006936 A BR112013006936 A BR 112013006936A BR 112013006936 A BR112013006936 A BR 112013006936A BR 112013006936 A2 BR112013006936 A2 BR 112013006936A2
- Authority
- BR
- Brazil
- Prior art keywords
- amide compound
- substituted amide
- pharmaceutical composition
- present
- lpa
- Prior art date
Links
- -1 amide compound Chemical class 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 abstract 1
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 abstract 1
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
composto de amida substituída. a presente invenção fornece um composto de amida substituída, tal como um composto representado pela seguinte fórmula estrutural, e assemelhados, que é útil como um ingrediente ativo de uma composição farmacêutica, em particular, uma composição farmacêutica para tratar doenças causadas pelo ácido lisofosfatídico (lpa). o compostos da presente invenção tem uma ação antagônica excelente sobre o receptor de lpa.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009220316 | 2009-09-25 | ||
PCT/JP2010/066572 WO2011037192A1 (ja) | 2009-09-25 | 2010-09-24 | 置換アミド化合物 |
PCT/JP2011/071635 WO2012039460A1 (ja) | 2010-09-24 | 2011-09-22 | 置換アミド化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013006936A2 true BR112013006936A2 (pt) | 2016-07-19 |
Family
ID=43795936
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012006686A BR112012006686B8 (pt) | 2009-09-25 | 2010-09-24 | compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa |
BR112013006936A BR112013006936A2 (pt) | 2009-09-25 | 2011-09-22 | composto de amida substituída |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012006686A BR112012006686B8 (pt) | 2009-09-25 | 2010-09-24 | compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa |
Country Status (17)
Country | Link |
---|---|
US (2) | US8669246B2 (pt) |
EP (1) | EP2481725B1 (pt) |
JP (1) | JP5708936B2 (pt) |
KR (1) | KR101678255B1 (pt) |
CN (1) | CN102548965B (pt) |
AU (1) | AU2010299114A1 (pt) |
BR (2) | BR112012006686B8 (pt) |
CA (1) | CA2774647C (pt) |
ES (1) | ES2532866T3 (pt) |
IL (1) | IL218723A0 (pt) |
MX (1) | MX2012003560A (pt) |
PL (1) | PL2481725T3 (pt) |
PT (2) | PT2481725E (pt) |
RU (2) | RU2563639C2 (pt) |
TW (1) | TW201117809A (pt) |
WO (1) | WO2011037192A1 (pt) |
ZA (1) | ZA201202106B (pt) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2481725E (pt) | 2009-09-25 | 2015-05-21 | Astellas Pharma Inc | Composto de amida substituído |
ES2537726T3 (es) * | 2010-09-24 | 2015-06-11 | Astellas Pharma Inc. | Compuesto de amida sustituida |
HU1000676D0 (en) | 2010-12-17 | 2011-02-28 | Pharmahungary 2000 Kft | Inhibitors of matrix metalloproteinase, pharmaceutical compositions thereof and use of them for preventing and treating diseases where the activation of mmp is involved |
AU2012296662A1 (en) | 2011-08-15 | 2014-03-27 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
ES2586213T3 (es) | 2011-10-31 | 2016-10-13 | Xenon Pharmaceuticals Inc. | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |
KR20140105445A (ko) | 2011-10-31 | 2014-09-01 | 제논 파마슈티칼스 인크. | 비아릴 에테르 술폰아미드 및 치료제로서의 그의 용도 |
ES2593533T3 (es) * | 2011-12-15 | 2016-12-09 | Pfizer Limited | Derivados de sulfonamida |
EA026393B1 (ru) | 2012-05-22 | 2017-04-28 | Дженентек, Инк. | N-замещенные бензамиды и их применение в лечении боли |
JP6309519B2 (ja) | 2012-07-06 | 2018-04-11 | ジェネンテック, インコーポレイテッド | N置換ベンズアミド及びその使用方法 |
CN103102325B (zh) * | 2013-01-16 | 2014-11-12 | 浙江大学宁波理工学院 | 一种2-溴代甲基-4-羧酸乙酯噻唑的合成方法 |
EP2968280A4 (en) | 2013-03-14 | 2016-08-10 | Genentech Inc | SUBSTITUTED TRIAZOLOPYRIDINES AND METHOD OF USE THEREOF |
US9493429B2 (en) | 2013-03-15 | 2016-11-15 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
CN105358174B (zh) | 2013-03-15 | 2019-03-15 | 酵活有限公司 | 具细胞毒性和抗有丝***的化合物以及其使用方法 |
CN103467281B (zh) * | 2013-07-25 | 2016-03-23 | 武汉英纳氏药业有限公司 | 一种苯酚衍生物及其应用 |
GB201314926D0 (en) | 2013-08-20 | 2013-10-02 | Takeda Pharmaceutical | Novel Compounds |
MX2016006936A (es) | 2013-11-27 | 2016-10-05 | Genentech Inc | Benzamidas sustituidas y metodos para usarlas. |
US10675355B2 (en) | 2013-12-27 | 2020-06-09 | Var2 Pharmaceuticals Aps | VAR2CSA-drug conjugates |
PL3086815T3 (pl) * | 2013-12-27 | 2022-06-13 | Zymeworks Inc. | Układy łącznikowe dla koniugatów leków zawierające ugrupowanie sulfonamidowe |
CN106715418A (zh) | 2014-07-07 | 2017-05-24 | 基因泰克公司 | 治疗化合物及其使用方法 |
WO2016041082A1 (en) | 2014-09-17 | 2016-03-24 | CDRD Ventures, Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
JP6733993B2 (ja) * | 2014-10-03 | 2020-08-05 | シンアフィックス ビー.ブイ. | スルファミドリンカー、スルファミドリンカーのコンジュゲート、及び調製の方法 |
CN107835805A (zh) | 2015-05-22 | 2018-03-23 | 基因泰克公司 | 被取代的苯甲酰胺和其使用方法 |
CN106243003B (zh) * | 2015-06-03 | 2018-03-09 | 上海海雁医药科技有限公司 | 环烃基取代的甲磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
US10253131B2 (en) * | 2015-07-13 | 2019-04-09 | University Of Delaware | Polymers prepared from functionalized dimethoxyphenol monomers |
US11525024B2 (en) | 2015-07-13 | 2022-12-13 | University Of Delaware | Bio-based polymers from raw lignocellulosic biomass |
WO2017035271A1 (en) | 2015-08-27 | 2017-03-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
CN105085234A (zh) * | 2015-08-31 | 2015-11-25 | 彭静 | 一种r-4-氯扁桃酸的制备方法 |
CN105085245A (zh) * | 2015-08-31 | 2015-11-25 | 彭静 | 一种r-4-氟扁桃酸的制备方法 |
CN105085235A (zh) * | 2015-08-31 | 2015-11-25 | 彭静 | 拆分制备s-4-氯扁桃酸的方法 |
CN105085244A (zh) * | 2015-08-31 | 2015-11-25 | 彭静 | 一种r-4-溴苦杏仁酸的制备方法 |
CN105152913A (zh) * | 2015-08-31 | 2015-12-16 | 彭静 | S-4-氟扁桃酸的制备方法 |
CN105085246A (zh) * | 2015-09-02 | 2015-11-25 | 彭静 | 一种r-邻氯扁桃酸的制备方法 |
CN105061190A (zh) * | 2015-09-02 | 2015-11-18 | 彭静 | 拆分制备s-五氟苦杏仁酸的方法 |
CN105085248A (zh) * | 2015-09-02 | 2015-11-25 | 彭静 | 拆分制备s-4-甲氧基扁桃酸的方法 |
CN105085247A (zh) * | 2015-09-02 | 2015-11-25 | 彭静 | 拆分制备r-4-甲氧基扁桃酸的方法 |
CN105085236A (zh) * | 2015-09-02 | 2015-11-25 | 彭静 | R-五氟苦杏仁酸的拆分制备方法 |
JP6987746B2 (ja) | 2015-09-28 | 2022-01-05 | ジェネンテック, インコーポレイテッド | 治療用化合物及びその使用方法 |
EP3380466A1 (en) | 2015-11-25 | 2018-10-03 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
US11951175B2 (en) | 2016-02-08 | 2024-04-09 | Synaffix B.V. | Bioconjugates containing sulfamide linkers for use in treatment |
EP3413922A1 (en) | 2016-02-08 | 2018-12-19 | SynAffix B.V. | Improved sulfamide linkers for use in bioconjugates |
CN109069658B (zh) | 2016-02-08 | 2022-10-14 | 西纳福克斯股份有限公司 | 用于靶向her2肿瘤的具有改善的治疗指数的抗体-缀合物以及用于改善抗体-缀合物的治疗指数的方法 |
US10766858B2 (en) | 2016-03-30 | 2020-09-08 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
PE20190980A1 (es) | 2016-10-17 | 2019-07-09 | Genentech Inc | Compuestos terapeuticos y metodos para utilizarlos |
US10793550B2 (en) | 2017-03-24 | 2020-10-06 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
EP3759098A1 (en) | 2018-02-26 | 2021-01-06 | Genentech, Inc. | Pyridine-sulfonamide compounds and their use against pain and related conditions |
EP3774801A1 (en) | 2018-03-30 | 2021-02-17 | F. Hoffmann-La Roche AG | Fused ring hydro-pyrido compounds as sodium channel inhibitors |
CA3102683A1 (en) * | 2018-06-07 | 2019-12-12 | Idorsia Pharmaceuticals Ltd | Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis |
AR119162A1 (es) * | 2019-06-18 | 2021-12-01 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-3-ilo |
US20220251342A1 (en) | 2019-08-09 | 2022-08-11 | Konica Minolta, Inc. | Resin composition, filamentous material, three-dimensional additively manufactured object, and method for producing three-dimensional additively manufactured object |
KR20220101137A (ko) | 2019-11-15 | 2022-07-19 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도 |
TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
CA3185689A1 (en) | 2020-06-03 | 2021-12-09 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
KR20240005892A (ko) | 2021-05-11 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
AU2022405082A1 (en) | 2021-12-08 | 2024-07-11 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
WO2024089216A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Novel sulfur-containing heteroaryl carboxamide compounds |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999019513A2 (en) | 1997-10-10 | 1999-04-22 | Lxr Biotechnology, Inc. | Methods for detecting compounds which modulate the activity of an lpa receptor |
WO2001060819A1 (fr) | 2000-02-18 | 2001-08-23 | Kirin Beer Kabushiki Kaisha | Nouveaux composes d'isoxazole et de thiazole et leur utilisation en tant que medicaments |
DE60234318D1 (de) | 2001-02-08 | 2009-12-24 | Ono Pharmaceutical Co | Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors |
JP4596314B2 (ja) | 2002-05-28 | 2010-12-08 | 小野薬品工業株式会社 | β−アラニン誘導体およびその用途 |
AU2003241834A1 (en) | 2002-06-26 | 2004-01-19 | Ono Pharmaceutical Co., Ltd. | Remedy for chronic disease |
CN1732161A (zh) * | 2002-09-06 | 2006-02-08 | 艾伦药物公司 | 1,3-二氨基-2-羟基丙烷前体药物衍生物 |
EP2565178A1 (en) | 2002-10-03 | 2013-03-06 | Ono Pharmaceutical Co., Ltd. | LPA Receptor Antagonists |
ATE528276T1 (de) | 2003-12-19 | 2011-10-15 | Ono Pharmaceutical Co | Lysophosphatidylsäurerezeptor-antagonistische verbindungen und ihre anwendungen |
JP5315611B2 (ja) * | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | S1p受容体結合能を有する化合物およびその用途 |
NZ568595A (en) * | 2005-12-14 | 2010-04-30 | Bristol Myers Squibb Co | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors |
TW200736234A (en) * | 2006-01-17 | 2007-10-01 | Astrazeneca Ab | Chemical compounds |
EP2767541A1 (en) * | 2008-03-03 | 2014-08-20 | Rxbio, Inc. | LPA receptor agonists and antagonists |
GB2470833B (en) * | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
PT2481725E (pt) | 2009-09-25 | 2015-05-21 | Astellas Pharma Inc | Composto de amida substituído |
ES2537726T3 (es) * | 2010-09-24 | 2015-06-11 | Astellas Pharma Inc. | Compuesto de amida sustituida |
-
2010
- 2010-09-24 PT PT108188640T patent/PT2481725E/pt unknown
- 2010-09-24 ES ES10818864.0T patent/ES2532866T3/es active Active
- 2010-09-24 CN CN201080042593.8A patent/CN102548965B/zh active Active
- 2010-09-24 BR BR112012006686A patent/BR112012006686B8/pt not_active IP Right Cessation
- 2010-09-24 KR KR1020127007569A patent/KR101678255B1/ko active IP Right Grant
- 2010-09-24 EP EP10818864.0A patent/EP2481725B1/en active Active
- 2010-09-24 PL PL10818864T patent/PL2481725T3/pl unknown
- 2010-09-24 TW TW099132379A patent/TW201117809A/zh unknown
- 2010-09-24 RU RU2012116505/04A patent/RU2563639C2/ru active
- 2010-09-24 CA CA2774647A patent/CA2774647C/en active Active
- 2010-09-24 RU RU2015117267A patent/RU2609021C2/ru active
- 2010-09-24 MX MX2012003560A patent/MX2012003560A/es active IP Right Grant
- 2010-09-24 WO PCT/JP2010/066572 patent/WO2011037192A1/ja active Application Filing
- 2010-09-24 JP JP2011533048A patent/JP5708936B2/ja not_active Expired - Fee Related
- 2010-09-24 AU AU2010299114A patent/AU2010299114A1/en not_active Abandoned
- 2010-09-24 US US13/498,159 patent/US8669246B2/en active Active
-
2011
- 2011-09-22 BR BR112013006936A patent/BR112013006936A2/pt not_active Application Discontinuation
- 2011-09-22 PT PT118269059T patent/PT2620433E/pt unknown
-
2012
- 2012-03-19 IL IL218723A patent/IL218723A0/en unknown
- 2012-03-22 ZA ZA2012/02106A patent/ZA201202106B/en unknown
-
2013
- 2013-03-04 US US13/783,858 patent/US8815920B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN102548965A (zh) | 2012-07-04 |
EP2481725A4 (en) | 2013-03-20 |
CA2774647C (en) | 2017-03-28 |
EP2481725B1 (en) | 2015-03-04 |
JP5708936B2 (ja) | 2015-04-30 |
CN102548965B (zh) | 2014-04-09 |
KR20120078700A (ko) | 2012-07-10 |
TW201117809A (en) | 2011-06-01 |
KR101678255B1 (ko) | 2016-11-21 |
IL218723A0 (en) | 2012-06-28 |
ZA201202106B (en) | 2013-05-29 |
BR112012006686B8 (pt) | 2021-05-25 |
US20120184521A1 (en) | 2012-07-19 |
CA2774647A1 (en) | 2011-03-31 |
US8669246B2 (en) | 2014-03-11 |
US8815920B2 (en) | 2014-08-26 |
PT2620433E (pt) | 2015-06-22 |
JPWO2011037192A1 (ja) | 2013-02-21 |
WO2011037192A1 (ja) | 2011-03-31 |
PL2481725T3 (pl) | 2015-08-31 |
RU2609021C2 (ru) | 2017-01-30 |
EP2481725A1 (en) | 2012-08-01 |
RU2563639C2 (ru) | 2015-09-20 |
PT2481725E (pt) | 2015-05-21 |
RU2012116505A (ru) | 2013-11-20 |
BR112012006686A2 (pt) | 2016-05-10 |
US20130231320A1 (en) | 2013-09-05 |
MX2012003560A (es) | 2012-10-05 |
ES2532866T3 (es) | 2015-04-01 |
RU2015117267A (ru) | 2015-11-10 |
AU2010299114A1 (en) | 2012-04-12 |
BR112012006686B1 (pt) | 2021-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013006936A2 (pt) | composto de amida substituída | |
CU20210009A7 (es) | Compuestos derivados de tieno pirrolo-triazina acetamida sustituida como inhibidores de la actividad inflamatoria de la proteína receptora tipo nod 3 (nlrp3) | |
BR112014017749A8 (pt) | Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo | |
NZ716840A (en) | Combination formulation of two antiviral compounds | |
BR112012030923B8 (pt) | Composto derivado de piperidinona como inibidor de mdm2 e composição farmacêutica compreendendo o mesmo | |
BR112014032873A2 (pt) | derivado de éster de ácido 2-aminonicotínico, e, bactericida | |
TN2018000043A1 (en) | Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors | |
BR112018003026A2 (pt) | composições compreendendo um inibidor de pi3k e um inibidor de hdac | |
CR20120328A (es) | Compuestos antiparasitarios de dihidroazol y composiciones que comprenden a los mismos | |
CL2012001821A1 (es) | Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
GT201000376A (es) | Compuestos organicos | |
CU20110207A7 (es) | Aril piridinas como inhibidoras de sintasa de aldosterona | |
BR112015027432A2 (pt) | 3-(4-isobutil-2-metilfenil)propanal como ingrediente de perfume | |
BR112012017564A2 (pt) | Formulação antimicrobiana | |
CR20130233A (es) | Derivados que quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinaza | |
BR112012032087A2 (pt) | composto, medicamento, e, uso de um composto | |
EA201270216A1 (ru) | Фармацевтический состав | |
IN2015MN00404A (pt) | ||
BR112012015725A2 (pt) | composição antitranspirante/desodorante aquosa | |
IN2014CN04530A (pt) | ||
MX340360B (es) | Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas. | |
CO6420341A2 (es) | Herbicidas novedosos | |
HN2010001647A (es) | INHIBIDORES DE HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA | |
PH12015502802A1 (en) | Formulation comprising a hypolipidemic agent | |
CO6410257A2 (es) | Herbicidas novedosos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |